Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with …